Compare Abeona Therapeutics Inc (ABEO) vs Carnival Corp (CCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Carnival Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Carnival Corp trades at $27.76 (market cap $39.71B). The key difference: Carnival Corp is far larger — about 93.6× Abeona Therapeutics Inc's market cap, and Carnival Corp pays a 1.55% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CCL | |
|---|---|---|
Market Cap | $424.33M | $39.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $33.99 |
52-Week Low | $4.17 | $23.89 |
Enterprise Value | $279.23M | $63.63B |
Dividend Yield | — | 1.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Carnival Corporation (CCL) trades at $28.99, up 0.69% today, with a bullish technical signal from moving averages and strong support at $28. The stock shows robust fundamentals, with revenue growing to $26.62B in 2025 and net income at $2.76B, while recent quarters have beaten EPS estimates. Analysts maintain a buy consensus with a $35.18 price target, and positive news highlights fleet expansion and sustainability initiatives.
The outlook for CCL is positive, driven by record travel demand, cost control, and debt reduction, offering potential upside to the consensus target. Risks include fuel price volatility, economic sensitivity, and high leverage, though improved cash flow and dividend reinstatement support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
